Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
LENZ Therapeutics’ $83.5 Million Series B Financing
Arcellx’s $4 Billion Collaboration with Kite
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
Bruker’s Acquisition of Inscopix
Wilson Sonsini Goodrich & Rosati advised Inscopix on the deal. Bruker Corporation, a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions,...
Boston Scientific’s Acquisition of Obsidio
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
BigHat’s $75 Million Series B Financing
Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...
Medical Solutions’ Acquisition of Matchwell
Wilson Sonsini Goodrich & Rosati advised Matchwell on the deal. Medical Solutions, one of the nation’s largest providers of total workforce solutions serving the healthcare industry,...
Boehringer Ingelheim’s Acquisition of Trutino Biosciences
Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences on the deal. Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire...
Codex DNA’s Collaboration and License Agreement with Pfizer
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, a leader in the development of automated solutions for on-demand synthesis of genes...
ABL Bio’s License Agreement with SANOFI
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...
Akili’s Licensing Agreement with TALi
Wilson Sonsini Goodrich & Rosati advised Akili on the deal. PureTech Health plc (PureTech), a clinical-stage biotherapeutics company, announced that its Founded Entity, Akili Interactive (Akili),...
NuVasive’s Acquisition of Simplify Medical
Wilson Sonsini Goodrich & Rosati advised Simplify Medical on the deal. NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally...